{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-055981","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.951032+00:00","generated_at":"2026-06-03T00:44:40.459601+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bicycle Therapeutics Q1 net loss narrows to $26.6M; cash $457M; Phase 2/3 trial initiated","bullets":["Cash and equivalents $457.0M as of Mar 31, 2024, down from $526.4M at Dec 31, 2023.","Net loss of $26.6M ($0.62 per share) vs $39.1M ($1.30) in Q1 2023; improvement helped by $8.2M retroactive UK R&D tax credits.","R&D expenses rose to $34.9M from $32.2M YoY, driven by BT8009 clinical program costs.","Initiated Phase 2/3 Duravelo-2 registrational trial for BT8009 in metastatic urothelial cancer; enrollment ongoing.","Mike Hannay promoted to Chief Product and Supply Chain Officer; multiple clinical data readouts expected in 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-055981","json":"https://secwatch.observer/filing/0001104659-24-055981.json","markdown":"https://secwatch.observer/filing/0001104659-24-055981.md","text":"https://secwatch.observer/filing/0001104659-24-055981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465924055981/0001104659-24-055981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465924055981/tm2413108d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:44:40.459601+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8a513cc221aa78db7aee9ff6fe1849cd76577771","claim":"BICYCLE THERAPEUTICS PLC reported first quarter ended March 31, 2024 results: net income Net loss was $26.6 million, EPS $(0.62) basic and diluted net loss per share.","evidence_excerpt":"Net loss was $26.6 million, or $(0.62) basic and diluted net loss per share, for the three months ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465924055981/0001104659-24-055981-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss was $26.6 million"},{"label":"EPS","value":"$(0.62) basic and diluted net loss per share"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}